Welcome to Capital Essence

Sign up for a FREE MEMBERSHIP to read tons of free content. Take a 30-DAY Trial Offer to access premium research and trading strategy. Check out our Investment Blog for the latest trading/investment ideas. If you want to go beyond the latest numbers, our Market Outlook will tell you why the market does what it does and what it means for the next day’s trading.

Trading Strategy – SPDR S&P Metals and Mining ETF

  One of the more noteworthy developments in recent days has been the move in commodities.  Copper briefly rose more than 1 percent to its highest level in nearly four years.  Gold futures for February delivery settled nearly half a percent higher at $1,297.20.  The SPDR S&P Metals and Mining ETF (XME) rose 1.58 percent …[read more]

SPDRs Report

Good Morning. This is Capital Essence’s U.S. Market ETFs Trading Map – SPDRs Sector Report for December 29, 2017. Editor’s note: this column was originally published on Capital Essence’s CEM News. It’s being republished as a bonus for the loyal readers. For more information about subscribing to CEM News, please click here. Below, daily, weekly …[read more]

Trading Strategy – Global X Copper Miners ETF

  One of the more noteworthy developments in recent days has been the move in copper.  Copper futures leapt to three-and-a-half-year peaks on Wednesday after a jump in China’s imports of the metal in November boosted expectations of stronger demand from the top consumer.  The Global X Copper Miners ETF (COPX) jumped 2.16 percent to …[read more]

SPDRs Report

Good Morning. This is Capital Essence’s U.S. Market ETFs Trading Map – SPDRs Sector Report for December 28, 2017. Editor’s note: this column was originally published on Capital Essence’s CEM News. It’s being republished as a bonus for the loyal readers. For more information about subscribing to CEM News, please click here. Below, daily, weekly …[read more]

Trading Strategy – SPDR S&P Biotech ETF

  One of the more noteworthy developments in recent days has been the move in biotech.  The group is showing signs of life after recent data showed market is firing on all cylinders.  The SPDR S&P Biotech ETF (XBI) rose 1.14 percent to 83.08, bringing its YTD gains to more than 40 percent, outperformed the …[read more]

Archives

Translate this Page